Redwood Pharma AB: Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 - 8 in Berlin for Partnering Discussions
Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 - 8 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company's therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform.
RP101 is the Company's lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials conducted in the US. The active substance is being repurposed and has been formulated in IntelliGel to control its release, reduce dosing and increase compliance. Redwood Pharma will initiate a clinical Phase II trial of RP101 in Europe. Dry eye disease is a large market with serious unmet needs - estimated to grow to USD 2.7 billion in 2022. RP101 will be the first therapy targeted towards a unique biological mechanism and the target patient population of postmenopausal women. With prior development data, this program will be faster to market and has lower capital needs and development risks than programs based on New Chemical Entities.
IntelliGel is Redwood Pharma's exclusive technology for the topical delivery of drugs to the front of the eye using a novel hydrogel based on poloxamers and water. IntelliGel is applied as an eye drop and gels upon contact with the eye. This transparent, lubricating, reversible thermogel allows for better compliance with fewer doses of medicines since the gel keeps the active substance in the eye longer; it allows for a reduction in the amount of active substance administered, a lowering of the number of doses and possible side-effects related to active substance. IntelliGel is currently used in dermatological products commercially sold in the US and China. IntelliGel can be used for both prescription-based, as well as, OTC products.